FT News Briefing The cost of China’s zero-Covid lockdown
May 9, 2022
China's unwavering zero-Covid policy has investors on edge, fueling economic uncertainty. Meanwhile, Africa's largest vaccine plant faces a precarious future after a production halt, raising concerns about vaccine supply. The show also dives into a legal battle between plant-based meat giants over patent rights, underscoring the competitive landscape of food biotechnology. With shifting priorities from scarcity to oversupply in vaccine production, the need for robust manufacturing capabilities in Africa has never been more critical.
AI Snips
Chapters
Transcript
Episode notes
Zero-COVID Policy Impact
- China's zero-COVID policy is hurting its economy and angering citizens.
- Despite the economic downturn, some foreign investors remain committed due to China's long-term potential.
Vaccine Plant Closure
- Africa's largest COVID vaccine plant halted production due to vaccine oversupply.
- Officials aim to revive it, recognizing the need for local vaccine production capacity for future pandemics.
Plant-Based Meat Battle
- Impossible Foods and Motif Foodworks are in a legal battle over a patent.
- Technology is central to the dispute, highlighting the growing importance of biotechnology in the plant-based food industry.